CompletedN/Aketamine

Ketamine Infusion as Sedative Analgesic in Severe ARDS

Sponsored by Interfaith Medical Center

NCT ID
NCT04818827
Target Enrollment
124 participants
Start Date
2020-02-01
Est. Completion
2021-02-14

About This Study

To evaluate whether ketamine is a safe sedative-analgesic agent to be used in an intensive care unit (ICU) setting as compared to traditionally used agents such as propofol, opioids, and midazolam

Conditions Studied

Intensive Care Unit SyndromeMechanical Ventilation ComplicationSedatives and Hypnotics Causing Adverse Effects in Therapeutic UseDelirium

Eligibility

Age:18 Years - 90 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 with an arterial partial pressure of oxygen divided by the inspired oxygen concentration (P/F) ratio \< 150 with a minimum 5 cm of positive end-expiratory pressure on a mechanical ventilator

Exclusion Criteria:

* post-cardiac arrest status,
* premorbid diagnosis of dementia,
* dependency on extra-corporeal therapies prior to or during ICU stay

Study Locations (1)

Interfaith Medical Center
New York, New York, United States

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source